Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001

Inhibikase Therapeutics, Inc.

First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).
Part A: ~140 patients, primary endpoint change in PVR at Week 24, double-blind placebo-controlled.
Part B: ~346 patients, primary endpoint change in 6MWD at Week 24, seamless transition from Part A.
Adaptive design includes a 12-week dose-titration phase; FDA confirmed study plan.
Trial to be conducted at up to ~180 sites worldwide; NDA filing timeline accelerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.